Anthony Walker

Recent Posts

Gene Therapy: Suspending Vector Immunity and Facilitating Re-Dosing?

Vector immunity is currently a major limiting factor in gene therapy. In the first place, patients with pre-existing immunity may either be ineligible for treatment or may require extremely high...
Learn More

Pharmaceutical Patents: an overview

Protecting new treatments and innovations is critical for drug developers. In this article, we provide of an overview of the history of patents, what a patent is, the general process to obtain one...
Learn More

Orkambi UK - Sound and Fury

By Anthony Walker, PhD, Managing Partner There’s a lot of sound and fury about Orkambi in the UK. Following a rejection from NICE, Vertex and NHS England have not been able to reach terms and the...
Learn More

Pharma Defying Gravity – How Much Longer?

Anthony Walker, PhD, Managing Partner, Alacrita Consulting
Learn More

mRNA vaccines: ready for prime time?

by Alex Yule, PhD, Associate, Alacrita Consulting
Learn More

Senolytics- taking aim at ageing cells

by Alex Yule, PhD, Associate, Alacrita Consulting
Learn More

Drugs and the human gut microbiome – beyond antibiotics

by Saadia Basharat, PhD, Consultant and Ashley Clark, Consultant Intern at Alacrita
Learn More

How best to Prioritize the IP Portfolio in Universities, Charities and Research Funding Bodies?

by Saadia Basharat, PhD, Consultant, Alacrita
Learn More

Brexit: What are the options for UK registered MAHs?

By Saadia Basharat, PhD, Consultant
Learn More

Zytiga – practice-changing clinical news but is it a home run?

ASCO provided practice-changing news for prostate cancer patients – Zytiga (abiraterone) added to standard hormone therapy in newly diagnosed high risk metastatic patients reduces the chance of death...
Learn More

The Wisdom of Henri Termeer, 1946-2017

What Can We Learn? Henri Termeer, one of the founding fathers of biopharma, died last week leaving a superb legacy of achievement in the industry. Always a colourful figure, some of his most...
Learn More

Healthcare Rationing or Simply Prioritization?

An interesting paper by Roland Turck (doi:10.1093/annonc/mdw548) puts oncology drug pricing into a certain perspective. For me, the most perceptive remark is that while oncology drugs represent only...
Learn More
1 2
Next

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2009-24 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.